Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
Novartis today announced presentation of a new analysis of Lutathera® (lutetium Lu 177 dotatate*) NETTER-1 data at the 2018 European Society for Medical Oncology (ESMO) congress examining the impact of Lutathera treatment on patients with low, medium or high liver tumor burden.
June 22, 2018
Advanced Accelerator Applications Announces First Patients Dosed in Two Clinical Studies with PSMA-R2 for Prostate Cancer Second Theragnostic Program for Oncology Enters the Clinic
AAA today announced that the first patients have been dosed in two Phase I/II clinical studies of radiolabeled PSMA-R2, a urea-based ligand of Prostate-Specific Membrane
Antigen (PSMA), which is commonly expressed on prostate cancer cells.
Latest Press Releases
February 7, 2019
Advanced Accelerator Applications Announces Health Canada Approval for Lutathera™, a Treatment for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)